Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup-studie (PMCF)

24 september 2026 uppdaterad av: Zimmer Biomet

Prospektiv klinisk uppföljningsstudie efter marknaden av kontinuummetallen på polyetenacetabulärsystemet

This is a prospective, multi-center, non-randomized, non-controlled study designed to obtain survival and outcome data on the Continuum Metal on Polyethylene Acetabular System when used in primary total hip arthroplasty.

Studieöversikt

Detaljerad beskrivning

The safety and performance of the Continuum Metal on Polyethylene Acetabular System will be confirmed by the assessment of survival and outcome data. Assessments will include standard scoring systems, radiographs and adverse event records. Data will be used to monitor pain, mobility, and survivorship of the Continuum Metal on Polyethylene Acetabular system in primary total hip arthroplasty. Metal ion (cobalt, chromium and titanium) and renal function (BUN, Creatinine and GFR) levels will be analyzed for a subset of the enrolled study subjects.

Studietyp

Observationell

Inskrivning (Faktisk)

195

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • California
      • Fremont, California, Förenta staterna, 94538
        • Sah Orthopaedic Associates
    • Colorado
      • Denver, Colorado, Förenta staterna, 80204
        • Denver Health Medical Center

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 75 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Patients from surgeons medical practice who are candidates for primary hip arthroplasty.

The study population will be comprised of 300 males and females who require primary total hip arthroplasty. Subjects will be enrolled at up to 7 clinical sites. Subjects must be geographically accessible throughout the study and be willing and able to attend required follow-up appointments. Candidates who express interest in study participation will be offered informed consent, and eligibility will be determined based upon the inclusion/exclusion criteria.

Beskrivning

Inclusion Criteria

  • Patient is 18 to 75 years of age, inclusive.

  • Patient is skeletally mature.

  • Patient qualifies for primary unilateral or bilateral (simultaneous or staged) total hip arthroplasty (THA) based on physical exam and medical history including the following:

    • Avascular necrosis (AVN)
    • Osteoarthritis
    • Inflammatory arthritis (i.e., Rheumatoid arthritis)
    • Post-traumatic arthritis
  • Patient has no history of previous prosthetic replacement device of any type, including surface replacement arthroplasty, endoprosthesis, etc. of the affected hip joint(s).

  • Patient has moderate, marked or disabling pain.

  • Patient is willing and able to provide written informed consent.

  • Patient is willing and able to cooperate in the required post-operative therapy.

  • Patient is willing and able to complete scheduled follow-up evaluations as described in the Informed Consent.

  • Patient has participated in the Informed Consent process and has signed the IRB approved informed consent.

Exclusion Criteria:

  • The patient is:

    • A prisoner
    • Mentally incompetent or unable to understand what participation in the study entails
    • A known alcohol or drug abuser
    • Anticipated to be non-compliant
  • The patient has a neuromuscular disorder, vascular disorder or other conditions that could contribute to prosthesis instability, prosthesis fixation failure or complications in postoperative care.

  • The patient has a neurologic condition in the ipsilateral or contralateral limb which affects lower limb function.

  • The patient has a diagnosed systemic disease that could affect his/her safety or the study outcome.

  • The patient is known to be pregnant.

  • The patient is unwilling or unable to give consent or to comply with the follow-up program.

  • The patient has received an investigational drug or device within the previous 6 months.

  • The patient has an active or latent infection in or about the affected hip joint or an infection distant from the hip joint that may spread to the hip hematogenously.

  • The patient has insufficient bone stock to fix the component. Insufficient bone stock exists in the presence of metabolic bone disease (i.e., osteoporosis), cancer, and radiation. Note: Dual Energy X-ray Absorptiometry (DEXA) may be used to assess the presence of adequate bone stock.

  • The patient has osteoradionecrosis in the affected hip joint.

  • The patient has a known sensitivity or allergic reaction to one or more of the implanted materials.

  • The patient has known local bone tumors and/or cysts in the operative hip.

  • The patient has a Body Mass Index (BMI) > 40.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Continuum Acetabular System

Patients receiving primary hip arthroplasty using the Continuum Metal on Polyethylene Acetabular System

Used in primary hip arthroplasty

Andra namn:
  • Total höftprotes, total höftprotes, primär höft

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Survivorship
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Based on removal or intended removal of the device and determined using the Kaplan-Meier method.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Safety / Adverse Events
Tidsram: Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Safety will be evaluated by monitoring the frequency and incidence of device related adverse events or unanticipated adverse device effects in investigational subjects.

Surgery, 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Pain and Function / HHS
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Pain and function will be measured using the Harris Hip Score self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Pain and Function / OHS
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Pain and function will be measured using the Oxford Hip Score self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Health Status / SF-12
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Health status will be measured using the SF-12 self assessment.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year
Health Status / Radiographic Parameters
Tidsram: 6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

X-rays will be evaluated for acetabular cup angle, acetabular cup migration, femoral stem position, femoral stem subsidence and femoral stem shift.

6 weeks, 6 months, 1 year, 2 year, 3 year, 5 year, 7 year, and 10 year

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Metal Ion / Cobalt
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Metal Ion / Chromium
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Metal Ion / Titanium
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / BUN
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / Creatinine
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years
Renal Function / GFR
Tidsram: Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Blood specimens analyzed for a subset of all enrolled study subjects to use as a comparator to blood levels in patients being studied under a separate clinical protocol. Adverse events reported for levels outside of normal range.

Pre-operatively and at 6 months, 1 year, 2 year and 5 years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Utredare

  • Studierektor: Hillary Overholser, Zimmer Biomet

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

29 mars 2011

Primärt slutförande (Faktisk)

17 juli 2026

Avslutad studie (Faktisk)

17 juli 2026

Studieregistreringsdatum

Först inskickad

25 februari 2011

Först inskickad som uppfyllde QC-kriterierna

28 februari 2011

Första postat (Beräknad)

2 mars 2011

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

24 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera